Cambridge Healthtech Institute’s 5th Annual

Immunomodulatory Therapeutic Antibodies for Cancer

Recent regulatory approvals and a succession of favorable clinical data from the checkpoint inhibitor programs of major pharmas are spearheading a new focus on immune system modulating protein therapeutics. However, this space has quickly become crowded with agents directed against similar targets, and issues with non-responders and a limited amount of capacity for clinical studies have created barriers for emerging companies wishing to enter this space. CHI’s Fifth Annual Immunomodulatory Therapeutic Antibodies for Cancer will explore the science and strategies behind developing unique approaches to the unmet medical needs in this market and offer important new updates on mechanistic understandings of efficacy, side effects and patient populations.

Preliminary Agenda

Keynote Presentation: Talk Title to be Announced

Gregory Adams, Ph.D., CSO, Eleven Biotherapeutics


MECHANISMS OF ACTION FOR T-CELL TARGETED IMMUNOTHERAPY

Immunomodulatory Antibodies- Potentiation by Fc Receptor Engagement

Rony Dahan, Ph.D., Postdoctoral Fellow, Laboratory of Molecular Genetics and Immunology, The Rockefeller University

The Role of Metabolism in Immune Response in Tumors

Allison S. Betof, M.D., Ph.D., Medical Oncology Fellow, Memorial Sloan Kettering Cancer Center

PI3Kgamma Is a Molecular Switch that Controls Immune Suppression

Megan Kaneda, Ph.D., Postdoctoral Researcher, Pathology, University of California, San Diego

Potential Role of NK Cells in Mediating Avelumab (hIgG1 Anti-Human PD-L1)’s Anti-Tumor Efficacy and Depletion of Immature Myeloid Cells in Preclinical Models

Yan Qu, Ph.D., Senior Principal Scientist, Pfizer


TARGET DISCOVERY FOR NEXT-GENERATION IMMUNOTHERAPIES

Functional Characterization of Macaque FcR and IgG Subtypes

Margie Ackerman, Ph.D., Assistant Professor, Engineering, Dartmouth College

Discovery and Development Strategies for New Non T-Cell Protein Immunotherapies

Michael Schickler, Ph.D., CEO, CureTech, Israel

Discovery and Development Strategies for New Small Molecule Immunotherapies

Nicola Wallis, Ph.D., Senior Director, Biology, Astex Therapeutics, Ltd., United Kingdom


IMMUNE SYSTEM PRIMING AND ACTIVATION

STING Adjuvant for Immune System Priming

Stephen Beers, Ph.D., Associate Professor, Cancer Immunology and Immunotherapy, University of Southampton, United Kingdom

Next-Generation Cancer Vaccines

Daniel L. Levey, Ph.D., Senior Director, Vaccine Research, Agenus

Oral T-Cell Activators Using Modified Attenuated Bacteria

Marc Mansour, Ph.D., Chief Business Officer, Vaximm AG


NON-RESPONDERS, SIDE EFFECTS AND TOXICOLOGY

Systematic Approaches to Identifying and Overcoming Resistance to Immune Checkpoint Inhibitors

Benjamin Izar, M.D., Ph.D., Medical Oncology Fellow, BIDMC and Center for Cancer Precision Medicine, Dana-Farber Cancer Institute and Broad Institute


PROTEIN ENGINEERING

A Novel, Dual-Specific Antibody Conjugate Targeting CD134 and CD137 Costimulates T Cells and Elicits Antitumor Immunity

Adam J. Adler, Ph.D., Professor, Immunology, University of Connecticut

PD-1/OX-40 Bifunctional that Simultaneously Blocks Immune Checkpoints and Activates TNF Superfamily Receptors

Taylor Schreiber, M.D., Ph.D., CSO, Shattuck Labs, Inc.




For more details on the conference, please contact:
Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
207-869-9199
ksimmons@healthtech.com

For exhibit & sponsorship opportunities, please contact: 
 
Rod Eymael
Manager, Business Development
781-247-6286
reymael@healthtech.com

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today